Bioorganic chemistryHumansPhthalazinesPiperazinesAntineoplastic AgentsDrug Screening Assays
Olaparib-Cediranib Hybrid as Dual PARP-VEGFR3 Inhibitor Elicits Antitumor Efficacy: Rational Design, Synthesis, Biological Evaluation and Construction of a Charge Convertible pH Responsive Nanoformulation.
Mandeep Rana, N VijayKamasewara Rao, Zih-Yao Yu, Ram Sharma, Jacob Mathew, Yu-Wen Chen, Sung-Bau Lee, Ankush Bansode, Tai-Ju Hsu, Ajmer Singh Grewal, Chun Hsu Pan, Santosh Guru, Kunal Nepali
Published: 202510.1016/j.bioorg.2025.109035
Abstract
Tempted by the clinical outcomes attained with the combination of poly(ADP-ribose) polymerase (PARP) and vascular endothelial growth factor receptor (VEGFR) inhibitors, a compendium of dual PARP-VEGFR inhibitory assemblages based on structural common…
Preview only. Read the full abstract at the source